Nexxus Commercial Suite brings multichannel data together
At Amazon’s Re:Invent meeting (Nov. 11-14, Las Vegas) IMS Health announced a decision to mount its cloud services, Nexxus Commercial Application Suite and IMS One cloud, wholly on Amazon’s AWS cloud platform. It’s not exactly a brave step into the unknown—AWS is a leading provider of cloud-based resources worldwide, and many pharma companies are already using it directly. But it does put essentially all of IMS’ cloud offerings in one basket, which are likely to be massive data loads, given that IMS Health tracks pharma and healthcare data around the world. And this is occurring as parts of the life sciences universe are deeply embedded in cloud services (such as clinical research) and others (such as manufacturing and supply chain management) are still grappling with cloud security and access issues.
The company has built out a suite of offerings for commercial activity, including integrated, multi-channel marketing campaign management, CRM, social media vigilance and cross-company analytics, and business intelligence and key performance indicator tools. The IMS One cloud integrates data sourced from IMS with client and third-party information sources, creating a single, trusted view that in turn can be accessed by the Nexxus commercial applications.
“Our hosting on AWS answers the growing customer need for flexible and accessible cloud solutions backed by IMS Health’s deep understanding of local markets and global information security practices,” said Sati Sian, senior vice president, Global Technology & Operations, IMS Health, in a statement.
Machine Health in Pharmaceutical Production
December 2nd 2024Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.